By otakuyassine3@gmail.com 
Eli Lilly and Company (NYSE:LLY – Get Free Report) and Exicure (NASDAQ:XCUR – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.
Institutional & Insider Ownership
82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by company insiders. Comparatively, 3.9% of Exicure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Eli Lilly and Company and Exicure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eli Lilly and Company | 23.51% | 85.24% | 16.19% |
| Exicure | N/A | -190.90% | -36.75% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Eli Lilly and Company and Exicure, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eli Lilly and Company | 0 | 3 | 16 | 0 | 2.84 |
| Exicure | 0 | 0 | 0 | 0 | 0.00 |
Eli Lilly and Company currently has a consensus price target of $1,009.72, suggesting a potential upside of 39.85%. Given Eli Lilly and Company’s stronger consensus rating and higher probable upside, analysts clearly believe Eli Lilly and Company is more favorable than Exicure.
Valuation & Earnings
This table compares Eli Lilly and Company and Exicure”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eli Lilly and Company | $45.04 billion | 15.20 | $10.59 billion | $11.71 | 61.66 |
| Exicure | $500,000.00 | 157.63 | -$16.91 million | ($4.81) | -2.59 |
Eli Lilly and Company has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Eli Lilly and Company has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Exicure has a beta of 3.74, suggesting that its share price is 274% more volatile than the S&P 500.
Summary
Eli Lilly and Company beats Exicure on 11 of the 14 factors compared between the two stocks.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
About Exicure
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company’s preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.